Cargando…
The Diagnostic Accuracy of Second Trimester Plasma Glycated CD59 (pGCD59) to Identify Women with Gestational Diabetes Mellitus Based on the 75 g OGTT Using the WHO Criteria: A Prospective Study of Non-Diabetic Pregnant Women in Ireland
The aim of this study was to evaluate the ability of second trimester plasma glycated CD59 (pGCD59), a novel biomarker, to predict the results of the 2 h 75 g oral glucose tolerance test at 24–28 weeks of gestation, employing the 2013 World Health Organisation criteria. This was a prospective study...
Autores principales: | Bogdanet, Delia, Toth Castillo, Michelle, Doheny, Helen, Dervan, Louise, Luque-Fernandez, Miguel-Angel, Halperin, Jose A., O’Shea, Paula M., Dunne, Fidelma P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267743/ https://www.ncbi.nlm.nih.gov/pubmed/35807179 http://dx.doi.org/10.3390/jcm11133895 |
Ejemplares similares
-
The utility of first trimester plasma glycated CD59 (pGCD59) in predicting gestational diabetes mellitus: A prospective study of non-diabetic pregnant women in Ireland
por: Bogdanet, Delia, et al.
Publicado: (2022) -
The ability of pGCD59 to predict adverse pregnancy outcomes: a prospective study of non-diabetic pregnant women in Ireland
por: Bogdanet, Delia, et al.
Publicado: (2022) -
The Role of Early Pregnancy Maternal pGCD59 Levels in Predicting Neonatal Hypoglycemia—Subanalysis of the DALI Study
por: Bogdanet, Delia, et al.
Publicado: (2022) -
Plasma glycated CD59 (gCD59), a novel biomarker for the diagnosis, management and follow up of women with Gestational Diabetes (GDM) – protocol for prospective cohort study
por: Bogdanet, D., et al.
Publicado: (2020) -
Plasma-glycated CD59 as an early biomarker for gestational diabetes mellitus: prospective cohort study protocol
por: Andrews, Chloe, et al.
Publicado: (2022)